Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers

IgG and IgA response after BNT162b2 mRNA vaccination

  • Gian Luca Salvagno Section of Clinical Biochemistry, University of Verona, Verona, Italy and Service of Laboratory Medicine, Pederzoli Hospital, Peschiera del Garda, Italy
  • Brandon Henry The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
  • Giovanni Di Piazza Medical Direction, Pederzoli Hospital, Peschiera del Garda, Italy
  • Laura Pighi Section of Clinical Biochemistry, University of Verona, Verona, Italy
  • Simone De Nitto Section of Clinical Biochemistry, University of Verona, Verona, Italy
  • Damiano Bragantini Infectious Diseases Unit, Pederzoli Hospital, Peschiera del Garda, Italy
  • Gianluca Gianfilippi Medical Direction, Pederzoli Hospital, Peschiera del Garda, Italy
  • Giuseppe Lippi Section of Clinical Biochemistry, University of Verona, Verona, Italy
DOI: https://doi.org/10.5937/jomb0-32373

Sažetak


Background: Most studies on immune response after coronavirus disease 2019 (COVID-19) vaccination focused on serum IgG antibodies and cell-mediated immunity, discounting the role of anti-SARS-CoV-2 neutralizing IgA antibodies in preventing viral infection. This study was aimed to quantify serum IgG and IgA neutralizing antibodies after mRNA COVID-19 vaccination in baseline SARS-CoV-2 seronegative healthcare workers.

Methods: The study population consisted of 181 SARS-CoV-2 seronegative healthcare workers (median age 42 years, 59.7% women), receiving two doses of Pfizer COVID-19 vaccine BNT162b2. Serum samples were collected before receiving the first vaccine dose, 21 days (before the second vaccine dose) and 50 days afterwards. We then measured anti-spike trimeric IgG (Liaison XL, DiaSorin), anti-spike receptor binding domain (RBD) IgG (Access 2, Beckman Coulter) and anti-spike S1 subunit IgA (ELISA, Euroimmun). Results were presented as median and interquartile range (IQR).

Results: Vaccine administration elicited all anti-SARS-CoV-2 antibodies measured. Thirty days after the second vaccine dose, 100% positivization occurred for anti-spike trimeric IgG and anti-spike RBD IgG, whilst 1.7% subjects remained anti-spike S1 IgA negative. The overall increase of antibodies level over baseline after the second vaccine dose was 576.1 (IQR, 360.7-867.8) for anti-spike trimeric IgG, 1426.0 (IQR, 742.0-2698.6) for anti-spike RBD IgG, and 20.2 (IQR, 12.5-32.1) for anti-spike S1 IgA. Significant inverse association was found between age and overall increase of anti-spike trimeric IgG (r=-0.24; p=0.001) and anti-spike S1 IgA (r=-0.16; p=0.028), but not with anti-spike RBD IgG (r=-0.05; p=0.497).

Conclusions: mRNA COVID-19 vaccination elicits sustained serum levels serum anti-spike trimeric IgG and anti-spike RBD IgG, while also modestly but significantly increasing those of serum anti-spike S1 IgA.

Reference

1. Lippi G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. Ann Transl Med 2020;8:497.
2. Delikhoon M, Guzman MI, Nabizadeh R, Norouzian Baghani A. Modes of Transmission of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) and Factors Influencing on the Airborne Transmission: A Review. Int J Environ Res Public Health 2021;18:395.
3. Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020 Sep;508:254-66.
4. Szkaradkiewicz-Karpińska AK, Szkaradkiewicz A. Towards a more effective strategy for COVID-19 prevention (Review). Exp Ther Med 2021;21:33.
5. World Health Organization. Vaccines and immunization: What is vaccination? Avaialble at: https://www.who.int/news-room/q-a-detail/vaccines-and-immunization-what-is-vaccination. Last accessed, May 24, 2021.
6. Fauci, A.S. The story behind COVID-19 vaccines. Science 2021;372:109.
7. Wu Z, Li T. Nanoparticle-Mediated Cytoplasmic Delivery of Messenger RNA Vaccines: Challenges and Future Perspectives. Pharm Res 2021;38:473-8.
8. Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. N Engl J Med 2021;384:1866-8.
9. Xiaojie S, Yu L, Lei Y, Guang Y, Min Q. Neutralizing antibodies targeting SARS-CoV-2 spike protein. Stem Cell Res. 2020 Dec 15;50:102125. doi: 10.1016/j.scr.2020.102125. Epub ahead of print.
10. Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection. Front Immunol 2020 Nov 30;11:611337.
11. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 2021;592:616-22.
12. Ketas TJ, Chaturbhuj D, Cruz-Portillo VM, Francomano E, Golden E, Chandrasekhar S, et al. Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. bioRxiv [Preprint]. 2021 Mar 11:2021.03.11.434841. doi: 10.1101/2021.03.11.434841.
13. Danese E, Montagnana M, Salvagno GL, Peserico D, Pighi L, De Nitto S, et al. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series. Clin Chem Lab Med. 2021 Apr 12. doi: 10.1515/cclm-2021-0339. Epub ahead of print.
14. McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines 2021;6:74.
15. The Lancet Infectious Diseases. The rocky road to universal COVID-19 vaccination. Lancet Infect Dis. 2021 May 14:S1473-3099(21)00275-9. doi: 10.1016/S1473-3099(21)00275-9. Epub ahead of print.
16. Borchering RK, Viboud C, Howerton E, Smith CP, Truelove S, Runge MCet al. Modeling of Future COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Rates and Nonpharmaceutical Intervention Scenarios - United States, April-September 2021. MMWR Morb Mortal Wkly Rep 2021;70:719-24.
17. Butler SE, Crowley AR, Natarajan H, Xu S, Weiner JA, Bobak CA, et al. Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. Front Immunol 2021;11:618685.
18. Lippi G, Sciacovelli L, Trenti T, Plebani M. Kinetics and biological characteristics of humoral response developing after SARS-CoV-2 infection: implications for vaccination. Clin Chem Lab Med. 2021 Jan 21. doi: 10.1515/cclm-2021-0038. Epub ahead of print.
19. Ejemel M, Li Q, Hou S, Schiller ZA, Tree JA, Wallace A, et al. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nat Commun 2020;11:4198.
20. Lippi G, Mattiuzzi C. Clinical value of anti-SARS-COV-2 serum IgA titration in patients with COVID-19. J Med Virol 2021;93:1210-1.
21. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med 2021;13:eabd2223.
22. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, et al. COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. J Clin Microbiol 2020;59:e02204-20.
23. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol 2020;5:eabe5511.
24. Varnaitė R, García M, Glans H, Maleki KT, Sandberg JT, Tynell J, et al. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients. J Immunol 2020;205:2437-46.
25. Quinti I, Mortari EP, Fernandez Salinas A, Milito C, Carsetti R. IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection. Front Cell Infect Microbiol 2021;11:655896.
26. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 2021;384:1412-23.
27. Saad-Roy CM, Morris SE, Metcalf CJE, Mina MJ, Baker RE, Farrar J, et al. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes. Science 2021;372:363-70.
Objavljeno
2021/06/03
Broj časopisa
Vol. 40 Br. 4 (2021): JMB
Rubrika
Original paper

Sva prava zadržana (c) 2021 Gian Luca Salvagno, Brandon Henry, Giovanni Di Piazza, Laura Pighi, Simone De Nitto, Damiano Bragantini, Gianluca Gianfilippi, Giuseppe Lippi

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.